The eye supplement category, explained: what the trials tested and what the shelf made of it

The macula is the small central region of the retina responsible for detailed vision. It is yellow, and the colour comes from three carotenoids concentrated in the tissue: lutein, zeaxanthin and meso-zeaxanthin. Collectively they are the macular pigment.

None of the three is synthesised in the body. They come from diet, principally dark leafy greens, maize and egg yolk, travel on lipoproteins, and are taken up into the retina by specific binding proteins that concentrate them far above blood levels.

Two properties explain the interest. The pigment absorbs short-wavelength light before it reaches the photoreceptors, and it acts as an antioxidant in tissue with one of the highest oxygen demands in the body. Both are physical chemistry rather than conjecture.

Crucially for a commercial category, the amount present can be measured through the closed eye. Macular pigment optical density is a real number, it responds to supplementation, and a 2024 network meta-analysis pooled the randomised trials that measured it. That measurability is what turned a nutritional observation into a shelf.

AREDS2 reported in 2013 and it was designed to answer two questions the first trial had left open.

The first was whether lutein and zeaxanthin could replace beta-carotene. The reason for asking was a safety signal rather than an efficacy one: supplemental beta-carotene had been associated with raised cancer risk in smokers, a finding later pooled in a 2010 meta-analysis and a 2023 update. A separate analysis looked at the amounts in retail multivitamins specifically, and a Cochrane review placed beta-carotene among the compounds studied for lung-cancer prevention.

The second was whether 80 mg of zinc was necessary or whether 25 mg would do. AREDS2 report 3 reported the secondary analyses.

The answers shaped the modern shelf. Lutein at 10 mg and zeaxanthin at 2 mg replaced the beta-carotene. The lower zinc arm progressed no differently. Report 4 reported cataract outcomes and report 28 followed the cohort out to ten years.

The Cochrane assessment, the 2023 Cochrane review, is the most conservative summary of what the whole body of work supports, and anybody taking this category seriously should read its plain-language summary.

AREDS2’s carotenoid arm was two ingredients at two amounts. The shelf it produced is mostly not that, and the gap between the two is the single most useful thing to understand about this category.

Three commercial pressures explain it.

Differentiation. A product that reproduces AREDS2 exactly is identical to every other product that does, and competes only on price. Adding ingredients creates something to say.

Perceived value. Twenty-four ingredients on a panel reads as better value than six, whatever the amounts. This is a well-understood effect and it is why the counts keep climbing.

Cost. Ten milligrams of lutein is one of the more expensive things in an eye formula. A blend that includes lutein at an undisclosed amount costs less to make than one that prints 10 mg, and reads similarly on the front of the bottle.

The result is a shelf on which a product carrying the actual trial formula sits beside products carrying four times as many ingredients, and the second kind usually looks more impressive.

Neither column is dishonest. They are answering different questions and a buyer should know which they are asking.

Beyond the AREDS six, a set of ingredients recurs across the shelf. It is worth knowing what each one actually has behind it, because almost none of it is an eye outcome.

The pattern across all of them is the same, and once you see it the shelf becomes much easier to read. Deficiency evidence is offered as supplementation evidence. Observational association is offered as effect. A trial in a different tissue is offered as a trial in the eye. None of those substitutions is a lie and none of them is what the label implies.